Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia

TM Macdonald; S Tong; J Myers; P Cannon; TV Nguyen; E Keenan; E Murray; A Harper; N Pritchard; NJ Hannan; KM Dane; AL Middleton; VP Kyritsis; SP Walker; TJ Kaitu'u-Lino

Journal article

Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia

TM Macdonald, S Tong, J Myers, P Cannon, TV Nguyen, E Keenan, E Murray, A Harper, N Pritchard, NJ Hannan, KM Dane, AL Middleton, VP Kyritsis, SP Walker, TJ Kaitu'u-Lino

Placenta | W B SAUNDERS CO LTD | Published : 2021

DOI: 10.1016/j.placenta.2021.01.018

Abstract

Introduction: Tissue Factor Pathway Inhibitor (TFPI) is a part of the extrinsic coagulation pathway, and highly expressed in the placenta. We aimed to assess its potential as a preeclampsia biomarker. Methods: Maternal plasma was prospectively collected at 36 weeks’ gestation. Circulating TFPI was measured in a nested case-control group (39 women who developed preeclampsia, 98 controls), before being measured in a larger independent cohort along with Placental Growth Factor (PlGF; 41 who developed preeclampsia, 954 controls). Circulating TFPI was then measured in women with underlying vascular disease, and also assessed in the plasma and placentas from women with preterm preeclampsia (delive..

View full abstract

University of Melbourne Researchers

Teresa MacDonald Author

Stephen Tong Author

Ping Cannon Author

Vi Nguyen Author

Related Projects (4)

IMPROVING THE PREDICTION AND DETECTION OF CONTRIBUTORS TO TERM STILLBIRTH

Stillbirths are a global human tragedy, with 1 in 130 of all pregnancies in Australia ending in stillbirth. We propose to use ultrasound and..

TRANSLATING NEW THERAPEUTICS AND DIAGNOSTICS FOR MAJOR PREGNANCY COMPLICATIONS

My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are deve..

DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA

Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the..

NEW DIAGNOSTICS TO PREDICT PREECLAMPSIA AND FETAL GROWTH RESTRICTION

Preeclampsia and fetal growth restriction are two of the most serious complications of pregnancy, claiming the lives of tens of thousands of..

Grants

Awarded by Norman Beischer Medical Research Foundation

Funding Acknowledgements

Funding for this work was provided by the National Health and Medical Research Council (#1065854, #1183854, #116071), and the Norman Beischer Medical Research Foundation; Australian Government Research Training Program Scholarship, and RANZCOG Taylor Hammond Scholarship to TM; National Health and Medical Research Council Fellowships to TKL (#1159261), NJH (#1146128) and ST (#1136418). The funders played no role in study design or analysis.